Skip to main content

ScholarsBetaWeill Cornell Medicine

Browse About Sign in

Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research5

FiltersClear all

Status

Recruiting1
Completed2
Terminated2

Study type

Interventional5

Phase

Phase 25
Phase 18
Phase 1/26
Phase 32
Not applicable2
Not reported2
Phase 2/31
Phase 41

Investigator

Dana Jeremy Lukin1
Doru Paul1
Howard Alan Fine1
John Allan1
Jia Ruan1

Department

Medicine4
Neurology1

Condition

Recurrence5
Carcinoma, Non-Small-Cell Lung11
Colitis, Ulcerative11
Prostatic Neoplasms11
Neoplasms9

Intervention type

Drug5
Procedure1

Sponsor type

Other academic2
WCM (investigator-initiated)2
Industry1

Start date

to

Has results posted3

Phase 2×Recurrence×Clear all

Showing 1–5 of 5 studiesSort:

RecruitingInterventional · Phase 2NCT02974647 ↗
Phase II Multicenter Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Jia Ruan

Show all 50

Show fewer

PI

Intervention: Drug: Ruxolitinib
Dates: Nov 2016 – Nov 2027 (est.)
Sponsor: Memorial Sloan Kettering Cancer Center

Lymphoma

CompletedInterventional · Phase 2NCT03557359 ↗

A Phase II, Open Label, Single Arm Study of Nivolumab for Recurrent or Progressive IDH Mutant Gliomas With Prior Exposure to Alkylating Agents

Howard Alan FinePI

Intervention: Drug: Nivolumab
Dates: Jun 2018 – Sep 2022· Results posted
Sponsor: Columbia University

Gliomas

TerminatedInterventional · Phase 2NCT03679624 ↗

A Phase II Study of Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia

Intervention: Drug: Ibrutinib · Drug: Daratumumab
Dates: Jul 2020 – Sep 2020· Results posted
Sponsor: Weill Medical College of Cornell University

Waldenstrom MacroglobulinemiaWaldenstrom's DiseaseWaldenström+5 more

TerminatedInterventional · Phase 2NCT04685499 ↗

Phase 2 Study of OBP-301 (Telomelysin ™) in Combination With Pembrolizumab and Stereotactic Body Irradiation in Patients With Head and Neck Squamous Cell Carcinoma With Inoperable, Recurrent or Progressive Disease

Intervention: Drug: OBP-301 · Drug: Pembrolizumab
Dates: May 2021 – Mar 2022· Results posted
Sponsor: Weill Medical College of Cornell University

Head and Neck Squamous Cell Carcinoma With Inoperable Recurrent or Progressive Disease

CompletedInterventional · Phase 2NCT04847739 ↗

Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas (STOMP-II)

Dana Jeremy LukinPI

Intervention: Procedure: Seton Placement · Drug: AVB-114
Dates: Sep 2021 – May 2025 (est.)
Sponsor: Avobis Bio, LLC

Perianal FistulaCrohn's Disease